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Abstract
The AIDS Cancer and Specimen Resource (ACSR) supports scientific discovery in the area of HIV/
AIDS-associated malignancies. The ACSR was established as a cooperative agreement between the
NCI (Office of the Director, Division of Cancer Treatment and Diagnosis) and regional consortia,
University of California, San Francisco (West Coast), George Washington University (East Coast)
and Ohio State University (Mid-Region) to collect, preserve and disperse HIV-related tissues and
biologic fluids and controls along with clinical data to qualified investigators. The available biological
samples with clinical data and the application process are described on the ACSR web site.
The ACSR tissue bank has more than 100,000 human HIV positive specimens that represent
different processing (43), specimen (15), and anatomical site (50) types. The ACSR provides special
biospecimen collections and prepares speciality items, e.g., tissue microarrays (TMA), DNA
libraries. Requests have been greatest for Kaposi's sarcoma (32%) and non-Hodgkin's lymphoma
(26%). Dispersed requests include 83% tissue (frozen and paraffin embedded), 18% plasma/serum
and 9% other. ACSR also provides tissue microarrays of, e.g., Kaposi's sarcoma and non-Hodgkin's
lymphoma, for biomarker assays and has developed collaborations with other groups that provide
access to additional AIDS-related malignancy specimens. ACSR members and associates have
completed 63 podium and poster presentations. Investigators have submitted 125 letters of intent
requests. Discoveries using ACSR have been reported in 61 scientific publications in notable
journals with an average impact factor of 7.
The ACSR promotes the scientific exploration of the relationship between HIV/AIDS and
malignancy by participation at national and international scientific meetings, contact with
investigators who have productive research in this area and identifying, collecting, preserving,
enhancing, and dispersing HIV/AIDS-related malignancy specimens to funded, approved
researchers at no fee. Scientific discovery has been advanced by this unique biorepository.
Investigators are encouraged to browse the ACSR Internet site for materials to enhance their own
scientific initiatives.
Published: 2 March 2007
Infectious Agents and Cancer 2007, 2:7 doi:10.1186/1750-9378-2-7
Received: 4 November 2006
Accepted: 2 March 2007
This article is available from: http://www.infectagentscancer.com/content/2/1/7
© 2007 Ayers et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Infectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 2 of 20
(page number not for citation purposes)
Review
Background
Human Immunodeficiency Virus (HIV) infection contin-
ues its global spread with almost 40 million HIV-infected
individuals worldwide. More than half are women [1].
While Acquired Immunodeficiency Syndrome (AIDS) is
most associated with opportunistic infections, adults and
children infected with HIV have well-recognized excess
risks for the development of malignancies [2]. Many of
these cancers are associated with known oncogenic viruses
such as: Epstein Barr virus (EBV) with non-Hodgkin's lym-
phoma, human herpes virus 8 (HHV8) with Kaposi's sar-
coma (KS), Hepatitis B (HBV) and Hepatitis C (HCV)
viruses with hepatocellular carcinoma and human papil-
loma virus (HPV) with squamous cell carcinomas of cer-
vix and anal canal. Other cancers, such as lung, are being
studied for their relationship to HIV infection. In the
developed world, cigarette smoking is common and HIV
infected smokers have an increased incidence of smoking-
related cancers of the lip, mouth, and pharynx [3]. With
the advent of highly active antiretroviral therapy (HAART)
in 1996, there was a dramatic reduction in the incidence
of non-Hodgkin's lymphomas (NHL) and especially KS.
However, apparently little reduction is suggested for the
other excess risk cancers including Hodgkin's lymphoma,
squamous cell carcinoma of anus, multicentric Castle-
man's disease in adults and leiomyosarcoma in children.
Despite HAART and public education the total number of
individuals living with HIV in the United States continues
unabated with more than a 50% increase since 1996. HIV
associated cancers in the HAART era are still among the
top causes of death in HIV/AIDS [4]. Furthermore it is of
concern that extended exposure of such a large population
of HIV infected individuals of all ages to nucleoside ana-
logs such as azidothymidine (AZT) and dideoxycytidine
(DDC), as well as, other potent AIDS drugs may induce
DNA damage leading to other significant associations
with cancer in the future.
The need to obtain and provide tumor tissue from
patients with AIDS was originally identified at a confer-
ence on AIDS Lymphoma in May, 1992. The request for a
resource for such specimens was made both by investiga-
tors participating in clinical trials research and laboratory
investigators. Thus the National Cancer Institute (NCI)
established the unique AIDS Malignancy Bank (AMB) in
1994 as a cooperative agreement to collect HIV positive
and control biological specimens, with associated clinical
data, to support translational research into HIV/AIDS-
related malignancies [5]. This AMB program continues as
the AIDS and Cancer Specimen Resource (ACSR) [6], sup-
porting broadened research interests in the area of HIV/
AIDS and oncogenic viruses [7] through collaborative
specimen assemblage. HAART associated reductions in
certain HIV/AIDS-related malignancies make these speci-
mens more difficult to acquire (e.g., KS and NHL), there-
fore the ACSR is a critical conduit for the collection,
preservation, banking and disbursement of scarce HIV/
AIDS-related malignant tissues and biological fluids to
qualified investigators.
In addition to serving as a resource for specimens acquired
from the consortia sites, the ACSR is a national repository
of specimens that reflects the temporal changes, and thus
the history, associated with HIV disease. During the
course of the last decade, the ACSR has established itself
as a singular specialized resource for collection, storage,
and provision of specimens with associated clinical, diag-
nostic, and epidemiologic data collected from HIV-
infected individuals participating in clinical trials, obser-
vational cohort studies, and other research studies con-
ducted by AIDS investigators both domestically and
internationally. During the life of the ACSR, the biorepos-
itory cost of specimens has decreased significantly making
the ACSR a good value to support research by RO1/R21
funded investigators engaged in HIV/AIDS malignancy
studies.
Specimens within the ACSR
The ACSR bank has more than 100,000 specimens from
HIV infected and control patients available from different
processing (43), specimen (15), and anatomical site (50)
types. Specimens are representative of the HIV/AIDS
evolving epidemic and are from a wide variety of patients,
including those with early, as compared to late-stage dis-
ease, multi-site autopsy specimens with involved and
uninvolved tissue, and specimens obtained from patients
with defined anti-retroviral or chemotherapy histories. In
addition, the inventory contains donations from the AIDS
epidemics in developing countries outside the United
States.
Special emphasis specimen and data acquisitions
• Detailed viral typing studies. The ACSR has expanded tis-
sue collection at international sites including Africa, Bra-
zil, and Thailand to obtain specimens from patients who
develop malignancies associated with infection from dif-
ferent subtypes of HIV, HHV-8, EBV, and HPV. These
types of specimens are critical for determining the role of
virus associated carcinogenesis in the natural epidemic
setting, as opposed to clinical settings where there is anti-
viral therapy intervention.
•  Neoplastic and non-neoplastic specimens from women.
Gynaecologic tissues, breast, and obstetrical specimens
from HIV-infected women come from collaborative
efforts with ongoing clinical studies of HIV-disease in
women, i.e. Women's Interagency HIV Study (WIHS).
Expansion of this collection to include specimens for
recently discovered agents and unusual malignanciesInfectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
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associated with HIV-disease is ongoing. The coordinated
study between WIHS and the Rwanda Women's HIV
Study, provides fresh gynaecological specimens (LEEPs,
uterine resections, and biopsies) and biological fluids
from infected women including normal tissue through
cervical cancer.
• Specimens from AIDS-related malignancies clinical treat-
ment trials. AIDS-related malignancy clinical trial groups
(ACTG) obtain specimens that are collected and stored
longitudinally. Samples retained from the early clinical
trials are now available through the ACSR to approved
investigators.
• Specialty sub-bank samples. Disease specific (lymphoma,
KS) tissue micro-arrays (TMAs) for rapid assessment of tis-
sue molecular targets or reagents (antibody, in situ probes,
etc) are available. Specimens preserved specifically for
transmission electron microscopy are available and pro-
vide optimal samples to carry out ultrastructural studies of
malignant, infectious, and reactive tissue processes. Spec-
imens preserved in fixatives recently shown to enhance
immunohistochemical and in situ hybridization results
are currently available or could be developed by request of
approved investigators.
• ACSR data interface. The ACSR has developed a national
computerized database of specimens with patient infor-
mation and clinical history. Over time, this system will
interface with electronic databases of other cooperative
banking groups, as well as with clinical trial groups. A ver-
sion of the ACSR database, stripped of patient identifiers,
is made available online; researchers can search for useful
specimens using various patient, specimen and clinical
criteria.
Investigator use of ACSR samples and clinical data
Investigators made 148 specimen availability inquires to
the ACSR, 88 resulted in full applications and 37 in short
applications. Of the full applications, 73 were approved to
receive multiple samples, 64 received samples, 8 are still
waiting funding or identification of appropriate speci-
mens, and 14 were not approved for a variety of reasons
including scientific merit, sample request size, or lack of
available specimens. The latter investigators were referred
to other bio-repositories or resources, when appropriate.
Of the full approved applications, 83% were for tissue,
18% for serum/plasma and 9% for cell lines, bone mar-
row, or urine. Some applications were approved for mixed
sample types. Of the 37 short form applications received,
36 were approved. The 23 remaining inquires included 19
for which no final application for samples was received
and researcher inquires that were referred to other biolog-
ical sample resources. Requests for Kaposi's sarcoma spec-
imens accounted for 32% of the total served requests,
lymphoma for 26%, and the remainder were for a variety
of other disease types and controls.
Investigators have used the ACSR's HIV infected and non-
infected control biological samples and clinical data to
contribute significant discoveries. Included are: markers
of selective B cell activation during lymphomagenesis [8],
effect of HIV integration site on cancer development [9],
role of macrophages [10], chemokines, cytokines and
growth factors in cancer [11], KHV induced transcrip-
tional reprogramming in KS cell types [12], correlation of
interleukin, CD4+ lymphopenia, viral load and disease
progression [13], persistent infections associated with
cancer, especially EBV [14] and human papillomaviruses
[15] and diagnostic assay development and validation
[16].
Investigations into the pathobiology of HIV infection
have used human tissue to provide translation from
important discoveries made in cell culture or animal stud-
ies. HIV insertion sites within human tissues including
somatic cells [17], macrophages and malignancies [18]
have been defined using ACSR provided infected human
tissue. The neuropathogenesis of AIDS dementia was
explored [19] using HIV infected brain tissue and techni-
cal resources within the ACSR. Likewise human associated
vasculopathy [20] and cardiomyopathy were elucidated
by translation to HIV/AIDS human tissues relevant find-
ings from a "murine AIDS" model [21].
The use of ACSR resources has resulted in sixty-one scien-
tific reports added to the scientific literature and others are
in preparation. Appendix I contains the list of these
reports. Table 1 lists all publishing journals and Figure 1
depicts impact factors for them. Eighty-three podium and
poster presentations have been made at local, national
and international scientific meetings through 2006 by
investigators using/promoting ACSR materials. Appendix
II contains a list of these presentations.
Developments within the ACSR
Evaluation of HIV DNA in ACSR specimens
The ACSR tested the suitability of: banked tissues to eval-
uate in vivo HIV sequences using an HIV bioinformatics
facility. HIV sequence analysis was performed using the
HIVbase® software (GeneJohnson, Inc., St. Augustine, FL).
HIV DNA was identifiable (at copy numbers greater than
1 per 10,000 cells) in:
a) >50% of blood derived T cell preparations
b) >33% of blood CD14+ monocytes
c) AIDS lymphomasInfectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
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d) AIDS lymphoid tissue
e) kidney and seminal vesicle tissues, and
f) >90% of brain tissues from patients with HIV dementia.
Studies of HIV gene sequence selection/evolution in
human HIV infected tissues from patients with AIDS
malignancies as compared to other classes of HIV related
disease can therefore be facilitated by ACSR resources
[19]. The ACSR has recently begun the development of an
AIDS lymphoma DNA library that can be made available
to interested and qualified investigators.
Tissue micro-arrays from ACSR specimens for translational research
Tissue micro-arrays (TMA) [22] are useful for a wide range
of research interests. One TMA tissue section can provide
diagnostic tissue core sections (0.6 mm in diameter or
greater) from literally hundreds of specimens, e.g., KS and
NHL, from HIV-positive and negative individuals, for
simultaneously testing. Immunohistochemical staining
and  in situ hybridization techniques are routinely
employed on TMAs. In general, all ACSR TMAs also con-
tain positive cores (e.g., cell culture lines) and negative
control cores along with the disease specific cores allow-
ing validation of novel tissue biomarkers. The ACSR pro-
vides non-Hodgkin's lymphoma and KS TMA slides to
Table 1: Journals publishing ACSR articles
Journals Weighted*Impact Factor# Number of Articles
Blood 9.654 9
Journal Of Virology 6.034 8
JAIDS – Journal Of Acquired Immune Deficiency Syndromes 3.345 5
Cancer Research 8.727 3
Journal Of Cellular Biochemistry 3.868 3
Nature Medicine 28.010 2
Lancet 20.158 2
Carcinogenesis 9.067 2
AIDS 5.517 2
Journal Of Neuroimmunology 3.598 2
Nature Genetics 24.695 1
JAMA – Journal Of The American Medical Association 9.522 1
Oncogene 6.872 1
American Journal Of Pathology 5.796 1
Cardiovascular Research 5.164 1
American Journal Of Epidemiology 3.978 1
Virology 3.540 1
American Journal Of Physiology – Heart And Circulatory Physiology 3.539 1
Journal Of Clinical Microbiology 3.503 1
AIDS Research And Human Retroviruses 3.069 1
Cellular Immunology 1.988 1
Journal Of Clinical Virology 1.744 1
Cancer Detection And Prevention 1.599 1
Journal Of Infectious Diseases 1.547 1
Anticancer Research 1.331 1
Ultrastructural Pathology 0.918 1
Cellular & Molecular Biology Letters 0.873 1
Articles in journals with impact factors 7.295 55
BMC Medical Informatics And Decision Making 2
Anatomical Record (Part B: New Anat.) 1
Annals Of Diagnostic Pathology 1
Current Opinion In Investigating Drugs 1
Humana Press 1
Articles in journals without impact factors 6
Total articles 61
* The impact factor of a journal varies by year. Each weighted impact factor is calculated by averaging the impact factor from the year of publication 
of each article.
# As impact factors are calculated from citations in a three year window following publication date, the last published impact factor is used for some 
more recent articles.Infectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
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Impact of ACSR Articles Figure 1
Impact of ACSR Articles. Journals that published ACSR related articles are shown with the bubble size representing the 
number of articles (count shown inside bubble) while the width represents the weighted average impact factor. For example, 
Nature Medicine, which published two ACSR articles, is shown at far right because it has the highest impact factor, 28.010.
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approved researchers interested in characterizing these
tumors using applicable tissue probes. Other TMAs are
planned, e.g., various subtypes of lymphoma character-
ized by immunohistochemistry and DNA.
Preview and selection of TMAs by researchers are
enhanced by the development and deployment of virtual
whole slide images of digitized TMA stained sections and
associated clinical data on an ACSR Internet site [23].
Online TMA and tissue core images (as in Figure 2), leg-
ends or data maps, and clinical data are linked for conven-
ient browsing [24,25]. Data is available in an industry
standard XML export format [26]. Printed data maps and
images of TMA slides are also available. TMAs are offered
as an enabling technology to expedite transitional
research in HIV/AIDS and particularly in HIV-related
malignancies, while conserving valuable specimens.
The quality of each TMA is directly related to the individ-
ual donor tissue core characteristics. Older archived paraf-
fin embedded tissues may be antigen negative or weakly
reactive and require optimal antigen retrieval methods
and high antibody titres for positive results. Core donor
tissues specifically prepared by optimal fixation and
processing provide the most favourable TMA sections for
studies with novel probes. Donor tissue characteristics are
available with each TMA to provide guidance to the inves-
tigator. Cut sections from each TMA are stained by H & E
to assure the presence of target tissues and by appropriate
immunohistochemical stains (IHC) to assure tissue
immunoreactivity for expected molecular targets prior to
listing TMA availability on the Internet site.
Structure
Organization of the ACSR
The national ACSR was formed as a cooperative agree-
ment between the NCI, Office of the Director, Division of
Cancer Treatment and Diagnosis (DCTD) and regional
ACSR consortia: University of California, San Francisco
for the West Coast, George Washington University for the
East Coast and The Ohio State University for the Mid-
Region. The ACSR steering committee, comprised of the
principal investigators from each consortium, developed
policies and procedures for standardized operation across
the organization. An outside Research Evaluation and
Decision Panel (REDP), comprised of experts in the field,
evaluates requests for specimens as shown in Figure 3. See
[6] for a detailed description of the program.
Privacy, Confidentiality, Authorization and Consent
Local Institutional Review Boards (IRBs) approve and
monitor the activity of each ACSR site. The local ACSR
maintains a research protocol to protect biologic sample
donor privacy and to maintain confidentially of clinical
data as required by federal standards including the
requirements of HIPPA [27]. Local IRB approval is
required for participation in the national ACSR program.
ACSR Internet site and national database
The ACSR established a database containing information
on ACSR specimen types and associated clinical data
obtained from patients with HIV/AIDS-related malignan-
cies and control specimens. Each consortium sends elec-
tronic de-identified data quarterly to the central ACSR
database. Records are maintained at each local site in
accordance with the local IRB approved protocol. Some
specimen collections have other databases that enable
investigators to perform studies on specimens linked with
a defined clinical or epidemiologic pedigree.
Guidelines
The ACSR has quality practices for biorepository opera-
tion that are consistent with International Society for Bio-
logical and Environmental Repositories (ISBER) best
practices [28], NCI Office of Biorepositories and Biospec-
imen Research (OBBR) guidelines [29] and AIDS Clinical
Trials Group (ACTG) Biomedical Research Institute (BRI)
guidelines [30].
Marketing
The ACSR has strategies to market the availability of HIV/
AIDS-associated malignancy specimens. Through word of
mouth, directed mailings, newsletters, and presence
(handouts and a specially designed ACSR booth) at
national and international meetings, the ACSR reaches
increasing numbers of potential researchers interested in
utilization of the resource and have steadily increased the
number of applications. The ACSR seeks feedback from its
investigator community to identify future needs, gaps,
and shortcomings.
Specimen disbursement
Identifying researcher needs
Investigators search on-line (using the Specimen Search
web page [6]) to identify specimen types that meet their
research requirements. Once researchers find specimens
of interest, they fill out a Letter of Intent (LOI) application
for acquiring the specimens. The ACSR has two applica-
tion types (short and long form) depending on the
number of specimens needed. All of the requirements for
researchers are available on the above Internet site. If the
researcher is unsure of whether needed samples and data
are available or has other questions regarding specimen
and data availability, the ACSR or NCI program director
can be contacted. Some of the general potential uses of
ACSR specimens are outlined in Table 2.
Letters of Intent and tracking
Full and short form LOI applications are accepted from
investigators throughout the year. Forms can be down-Infectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
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Sample TMA image from the virtual microscope section on the ACSR Mid-region Internet site for viewing TMS core tissues by  interested investigators Figure 2
Sample TMA image from the virtual microscope section on the ACSR Mid-region Internet site for viewing TMS core tissues by 
interested investigators.
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ACSR organization Figure 3
ACSR organization.
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loaded from the Letter of Intent Application Form web page
[6]. The application process requires minimal paper work
and is outlined in detail on the web site. When specimens
are approved for delivery, they are packaged and shipped
(on dry ice, when appropriate) according to International
Air Transport Association (IATA) regulations. The ACSR
works with other biological material resources and refers
investigators to these resources if specimens are not avail-
able within the ACSR cooperative group. The confidential
ACSR LOI tracking system allows inquiry tracking, provid-
ing details of requests and the status of shipments without
disclosing research directions outside of the ACSR staff.
Sample Quality control
Investigators who receive ACSR specimens assist in the
ACSR Quality Assessment Program by evaluating the
quality of specimens they receive and returning a written
evaluation document to the ACSR. For example, users
have reported that blood stored by the ACSR yielded
>90% high quality RNA and DNA and viability of PBMCs
exceeding 50% in samples stored for up to five years. A
return evaluation card is included with each sample ship-
ment.
Random samplings of specimens are regularly tested for
preservation of RNA and DNA and the viability of cells in
frozen storage. Many of the banked specimens, however,
are too small to allow extensive pre-testing that requires
destructive sampling. The quality of stored biological
samples can generally be anticipated based on specimen
type, type of fixative or processing, length of storage, stor-
age method and the type of testing anticipated by the
investigator [31,32]. Investigators are encouraged to verify
the use of specified biological sample types before under-
taking their planned study.
Cost to investigators
Samples are provided to approved, funded investigators
working in non-profit research settings at no fee. Investi-
gators working in a commercial setting may also obtain
samples if approved by the REDP but a fee per sample and
for service may be applied.
Table 2: Potential uses of ACSR banked specimens
Type Use
Autopsies (multi-site) frozen & fixed DNA and protein studies within individuals; involved vs. uninvolved tissues
Tissue array analyses Comparison of antigen expression between 
many patient tumors
Diseased tissue specific cytokine, virus, antigen 
expression
Frozen lymphoma, KS and tumor tissues DNA, RNA, and protein array studies; viral discovery/strain variation studies
Non Hodgkin's lymphoma (AIDS & non-AIDS) 
epidemiology study (serum & fixed tissue)
Serologic studies on cases vs. controls for cytokine, viral antigen, serum proteins. Coupled with 
epidemiologic data in collaboration with Dr. Elizabeth Holly test disease associations, risk factors, 
transmission risk factors, resistance factors, lymphoma tissue, DNA/protein correlation with 
serum factors/disease associations.
AIDS Malignancy Consortium clinical trial 
specimens
Longitudinal, trial associated specimens for analyses of disease specific markers in collaboration 
with AMC
Serum specimens from cross-sectional survey 
in Thailand
Studies on low KS prevalence untreated HIV & serum cohort Infected vs. uninfected age & sex 
matched specimen comparisons
Studies on HIV, non-US viral isolates. Repeat blood draws from HIV+ individuals available for rate 
of variation studies.
Ano-genital specimens from men and women 
HIV+/HIV-
Study role of HIV strains in early stages of ano-genital carcinogenesis
Plastic embedded tissue suitable for 
transmission electron microscopy
Evaluation of virus identity, morphogenesis, and cytopathology in various disease statesInfectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 10 of 20
(page number not for citation purposes)
Specimen collection and processing
Specimens from a wide variety of HIV infected patients
and selected controls are processed based on laboratory
standard protocols described in the ACSR standard oper-
ating procedure manual, accessible through the Process
Specimens (Protocols) web page [6]. This manual provides
instructions for the collection, preparation and shipment
of specimens among the ACSR sites and to approved
investigators. Cooperative groups interfacing with the
ACSR can use the ACSR manual as a resource for their
activities.
Specimens donated individually
Each ACSR site has developed a consortium of patholo-
gists and clinicians at participating sites who collect and
contribute specimens and clinical information to the
ACSR. If samples are specifically collected for the ACSR,
each donor signs an ACSR informed consent document
and a HIPPA document approved by the local IRB. Sam-
ples from archived paraffin embedded tissues and associ-
ated clinical data are acquired according to local hospital
rules, IRB approved protocols including federal HIPPA
waiver of informed consent for use of personal medical
information preparatory to research [27]. All samples and
clinical data are coded when they are entered into the
local ACSR site, de-identified before being placed on the
web and all samples and clinical data released to investi-
gators are anonymous.
Samples donated by HIV/AIDS treatment and 
epidemiology groups
The ACSR is directly affiliated with the AIDS Malignancy
Consortium (AMC) [33], a national group that conducts
clinical trials in patients with AIDS-related malignancies.
This affiliation allows the banking of well-characterized,
longitudinal specimens from a variety of clinical trials for
ultimate use by approved researchers. This association
provides material for the search for prognostic markers
and promising therapeutic regimens. Using the AMC rela-
tionship as a model, further group affiliations have been
developed, such as relationships with the Women's Inter-
agency HIV Study (WIHS), the AIDS Clinical Trials Group
(ACTG), the San Francisco gay men's health study, the
national ano-genital cancer study, San Francisco lym-
phoma study of 1600 NHL patients and 2500 random
controls, natural history study of HHV8/KSHV in homo-
sexual men in the San Francisco area, the Rwanda HIV
women's study, and a variety of smaller studies. The WIHS
is a unique study, which provides interval blood speci-
mens and fresh colposcopy specimens from 2809 HIV-
positive and 959 negative women who have cervical
lesions. This study provides valuable pre and post diag-
nostic biologic specimens.
Specimen collections donated or accessed through a 
referral process
Where large collections of specimens are in place within
established programs, the ACSR can act as a broker
between the ACSR research applicant and the "resource"
tissue bank. Where there are biologic sample collections
that have been placed at risk because of funding loss, tis-
sue bank down sizing or other reasons, the ACSR can
accept transfer of banked biological sample collections
with their attendant databases, for inclusion in the overall
ACSR program. Examples of the first type of relationship
includes: interfaces with the National Neuro AIDS Bank
(NNAB), the National Neurological disease Tissue Con-
sortium (NNTC), the UCLA Brain Bank Program, various
multi-center AIDS cohort study (MACS) groups, the UCSF
AIDS Specimen Bank (ASB) and the Hawaiian AIDS natu-
ral history cohort study. Examples of the second type,
where specimens have been transferred to the ACSR
include: the San Francisco gay men's HHV-8 natural his-
tory cohort, and the US Department of Defence Thailand
vaccine trial serum specimen bank.
The ACSR approach to the changing epidemic
The USA alone has about 950,000 people living with HIV
infection (about a quarter of whom are not aware of their
infection). Prospective and longitudinal samples across
the time-line of the changes in the epidemic are critical to
understanding the epidemic as it evolves. Collection of
such specimens has been a goal of the ACSR. The ACSR is
taking into consideration the evolution of HIV-associated
cancers (e.g., the higher rate of head and neck cancer in
HIV patients in Africa) by establishing pertinent collabo-
rations. Through collaboration, the ACSR is reaching out
to heavily HIV/AIDS affected areas, such as Africa, Brazil,
Russia, and Thailand to acquire relevant specimens.
Conclusion
The ACSR makes available large numbers of HIV/AIDS-
related malignancy specimens for funded, approved
researchers at no fee. Scientific discovery has been
advanced by this unique program through promotion of
interest in and access to HIV/AIDS human tissues for pri-
mary and translational research. Investigators using ACSR
specimens have shared their discoveries with the scientific
community through publications in notable scientific
journals and at meetings. Investigators are encouraged to
browse the ACSR Internet site or contact the ACSR for
specimens to enhance their own scientific initiatives.
Competing interests
The author(s) declare that they have no competing inter-
ests.Infectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 11 of 20
(page number not for citation purposes)
Authors' contributions
MSM wrote the initial draft of the manuscript. LWA had
primary responsibility for rewriting, reviewing, incorpo-
rating comments and editing the manuscript. JMO also
edited the manuscript. All authors provided comments of
various drafts, participated in direction setting discussions
and reviews and have read and approved the final version.
Appendix I – Articles using ACSR resources
1. Kaplan LD, Shiramizu B, Herndier B, Hahan J, Meeker
TC, Ng V, Volberding PA, and McGrath MS. Influence of
molecular characteristics on clinical outcome in HIV-asso-
ciated non-Hodgkin's lymphoma: Identification of a sub-
group with favorable clinical outcome. Blood 85:1727–
1735; 1995.
2. Renne R, Zhong W, Herndier B, McGrath MS, Abbey
NW, Kedes D, Ganem D. Lytic growth of Kaposi's sarcoma
– associated herpesvirus (human herpesvirus 8) in B cell
lymphoma cells in culture. Nature Med. 2:342–346;1996.
3. Przybylski GK, Goldman J, Ng VL, McGrath MS, Hern-
dier BG, Schenkein DP, Monroe JG, Silberstein LE. Evi-
dence for early B-cell activation preceding the
development of Epstein-Barr virus-negative acquired
immunodeficiency syndrome-related lymphoma. Blood.
1996 Dec 15;88(12):4620–9.
4. Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H,
Renne R, Beneke J, Pudney J, Anderson DJ, Ganem D,
Haase AT. Kaposi's sarcoma-associated herpesvirus gene
expression in endothelial (spindle) tumor cells. J Virol.
1997 Jan;71(1):715–9.
5. Ng VL, Hurt MH, Herndier BG, Fry KE, McGrath MS. VH
gene use by HIV type 1-associated lymphoproliferations.
AIDS Res Hum Retroviruses. 1997 Jan 20;13(2):135–49.
6. Orenstein JM, Alkan S, Blauvelt A, Jeang KT, Weinstein
MD, Ganem D, Herndier B. Visualization of human her-
pesvirus type 8 in Kaposi's sarcoma by light and transmis-
sion electron microscopy. AIDS. 1997 Apr;11(5):F35–45.
7. Holly EA, Lele C, Bracci P. Non-Hodgkin's lymphoma
in homosexual men in the San Francisco Bay Area: occu-
pational, chemical, and environmental exposures. J
Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jul
1;15(3):223–31.
8. Picchio GR, Sabbe RE, Gulizia RJ, McGrath M, Herndier
BG, Mosier DE. The KSHV/HHV8-infected BCBL-1 lym-
phoma line causes tumors in SCID mice but fails to trans-
mit virus to a human peripheral blood mononuclear cell
graft. Virology. 1997 Nov 10;238(1):22–9.
9. Mallery SR, Landwehr DJ, Ness GM, Clark YM, Hohl
CM. Thiol redox modulation of tumor necrosis factor-
alpha responsiveness in cultured AIDS-related Kaposi's
sarcoma cells. J Cell Biochem. 1998 Mar 1;68(3):339–54.
10. Palefsky JM, Holly EA, Hogeboom CJ, Ralston ML,
DaCosta MM, Botts R, Berry JM, Jay N, Darragh TM. Viro-
logic, immunologic, and clinical parameters in the inci-
dence and progression of anal squamous intraepithelial
lesions in HIV-positive and HIV-negative homosexual
men. J Acquir Immune Defic Syndr Hum Retrovirol. 1998
Apr 1;17(4):314–9.
11. Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jag-
irdar J, Thomas B, Ioachim HL, Litzky LA, Brambilla EM,
Minna JD, Gazdar AF. Comparison of molecular changes
in lung cancers in HIV-positive and HIV-indeterminate
subjects. JAMA. 1998 May 20;279(19):1554–9.
12. Li M, MacKey J, Czajak SC, Desrosiers RC, Lackner AA,
Jung JU. Identification and characterization of Kaposi's
sarcoma-associated herpesvirus K8.1 virion glycoprotein.
J Virol. 1999 Feb;73(2):1341–9.
13. Orenstein JM, Wahl SM. The macrophage origin of the
HIV-expressing multinucleated giant cells in hyperplastic
tonsils and adenoids. Ultrastruct Pathol. 1999 Mar-
Apr;23(2):79–91.
14. Mallery SR, Clark YM, Ness GM, Minshawi OM, Pei P,
Hohl CM. Thiol redox modulation of doxorubicin medi-
ated cytotoxicity in cultured AIDS-related Kaposi's sar-
coma cells. J Cell Biochem. 1999 May 1;73(2):259–77.
15. Zong JC, Ciufo DM, Alcendor DJ, Wan X, Nicholas J,
Browning PJ, Rady PL, Tyring SK, Orenstein JM, Rabkin
CS, Su IJ, Powell KF, Croxson M, Foreman KE, Nickoloff
BJ, Alkan S, Hayward GS. High-level variability in the
ORF-K1 membrane protein gene at the left end of the
Kaposi's sarcoma-associated herpesvirus genome defines
four major virus subtypes and multiple variants or clades
in different human populations. J Virol. 1999
May;73(5):4156–70.
16. Poole LJ, Zong JC, Ciufo DM, Alcendor DJ, Cannon JS,
Ambinder R, Orenstein JM, Reitz MS, Hayward GS. Com-
parison of genetic variability at multiple loci across the
genomes of the major subtypes of Kaposi's sarcoma-asso-
ciated herpesvirus reveals evidence for recombination and
for two distinct types of open reading frame K15 alleles at
the right-hand end. J Virol. 1999 Aug;73(8):6646–60.
17. Holly EA, Lele C, Bracci PM, McGrath MS. Case-con-
trol study of non-Hodgkin's lymphoma among womenInfectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 12 of 20
(page number not for citation purposes)
and heterosexual men in the San Francisco Bay Area, Cal-
ifornia. Am J Epidemiol. 1999 Aug 15;150(4):375–89.
18. Aoki Y, Tosato G, Nambu Y, Iwamoto A, Yarchoan R.
Detection of vascular endothelial growth factor in AIDS-
related primary effusion lymphomas. Blood. 2000 Feb
1;95(3):1109–10.
19. Martin JN, Amad Z, Cossen C, Lam PK, Kedes DH,
Page-Shafer KA, Osmond DH, Forghani B. Use of epide-
miologically well-defined subjects and existing immun-
ofluorescence assays to calibrate a new enzyme
immunoassay for human herpesvirus 8 antibodies. J Clin
Microbiol. 2000 Feb;38(2):696–701.
20. McGrath MS, Shiramizu B, Herndier BG. Clonal HIV
in the pathogenesis of AIDS-related lymphoma. In Infec-
tious Causes of Cancer Targets for Intervention. Edited by
Goedert JJ. New Jersey: Humana Press; 2000:231–242.
21. Edelman DC, Ketema F, Saville RD, Herman J, Sill AM,
Gill PS, Blattner WA, Constantine NT. Specifics on the
refinement and application of two serological assays for
the detection of antibodies to HHV-8. J Clin Virol. 2000
May;16(3):225–37.
22. Aoki Y, Yarchoan R, Braun J, Iwamoto A, Tosato G.
Viral and cellular cytokines in AIDS-related malignant
lymphomatous effusions. Blood. 2000 Aug
15;96(4):1599–601.
23. Mallery SR, Pei P, Kang J, Ness GM, Ortiz R, Tou-
halisky JE, Schwendeman SP. Controlled-release of doxo-
rubicin from poly(lactide-co-glycolide) microspheres
significantly enhances cytotoxicity against cultured AIDS-
related Kaposi's sarcoma cells. Anticancer Res. 2000 Sep-
Oct;20(5A):2817–25.
24. Mallery SR, Pei P, Kang J, Zhu G, Ness GM, Schwende-
man SP. Sustained angiogenesis enables in vivo transplan-
tation of mucocutaneous derived AIDS-related Kaposi's
sarcoma cells in murine hosts. Carcinogenesis. 2000
Sep;21(9):1647–53.
25. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De
Rosa SC, Herzenberg LA, Herndier BG, Andersson J,
McCune JM. Increased production of IL-7 accompanies
HIV-1-mediated T-cell depletion: implications for T-cell
homeostasis. Nat Med. 2001 Jan;7(1):73–9.
26. Vilchez RA, Lednicky JA, Halvorson SJ, White ZS, Kozi-
netz CA, Butel JS. Detection of polyomavirus simian virus
40 tumor antigen DNA in AIDS-related systemic non-
Hodgkin lymphoma. J Acquir Immune Defic Syndr. 2002
Feb 1;29(2):109–16.
27. McGrath MS, Kahn JO, Herndier BG. Development of
WF10, a novel macrophage-regulating agent. Curr Opin
Investig Drugs. 2002 Mar;3(3):365–73.
28. Shivapurkar N, Harada K, Reddy J, Scheuermann RH,
Xu Y, McKenna RW, Milchgrub S, Kroft SH, Feng Z,
Gazdar A. Presence of simian virus 40 DNA sequences in
human lymphomas. The Lancet, March 9, 2002;
359:851–852.
29. Vilchez RA, Madden CR, Kozinetz CA, Halvorson SJ,
White ZS, Jorgensen JL, Finch CJ, Butel JS. Association
between simian virus 40 and non-Hodgkin lymphoma.
Lancet. 2002 Mar 9;359(9309):817–23.
30. Lore K, Sonnerborg A, Brostrom C, Goh LE, Perrin L,
McDade H, Stellbrink HJ, Gazzard B, Weber R, Napoli-
tano LA, van Kooyk Y, Andersson J.Accumulation of DC-
SIGN+CD40+ dendritic cells with reduced CD80 and
CD86 expression in lymphoid tissue during acute HIV-1
infection. AIDS. 2002 Mar 29;16(5):683–92.
31. Gascon RL, Narvaez AB, Zhang R, Kahn JO, Hecht FM,
Herndier BG, McGrath MS. Increased HLA-DR expression
on peripheral blood monocytes in subsets of subjects with
primary HIV infection is associated with elevated CD4 T-
cell apoptosis and CD4 T-cell depletion. J Acquir Immune
Defic Syndr. 2002 Jun 1;30(2):146–53.
32. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDer-
mott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D,
Grillo-Lopez A, Shuman MA. Rituximab therapy for CNS
lymphomas: targeting the leptomeningeal compartment.
Blood. 2003 Jan 15;101(2):466–8. Epub 2002 Sep 5.
33. Zenger E, Abbey NW, Weinstein MD, Kapp L, Reis J,
Gofman I, Millward C, Gascon R, Elbaggari A, Herndier
BG, McGrath MS. Injection of human primary effusion
lymphoma cells or associated macrophages into severe
combined immunodeficient mice causes murine lympho-
mas. Cancer Res. 2002 Oct 1;62(19):5536–42.
34. Spiller OB, Robinson M, O'Donnell E, Milligan S,
Morgan BP, Davison AJ, Blackbourn DJ. Complement reg-
ulation by Kaposi's sarcoma-associated herpesvirus ORF4
protein. J Virol. 2003 Jan;77(1):592–9.
35. Romer DJ, Suster S. Use of virtual microscopy for
didactic live-audience presentation in anatomic pathol-
ogy. Ann Diagn Pathol. 2003 Feb;7(1):67–72.
36. Dittmer DP. Transcription profile of Kaposi's sarcoma-
associated herpesvirus in primary Kaposi's sarcoma
lesions as determined by real-time PCR arrays. Cancer Res.
2003 May 1;63(9):2010–5.Infectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 13 of 20
(page number not for citation purposes)
37. Mallery SR, Morse MA, Wilson RF, Pei P, Ness GM,
Bradburn JE, Renner RJ, Schuller DE, Robertson FM.
AIDS-related Kaposi's sarcoma cells rapidly internalize
endostatin, which co-localizes to tropomysin microfila-
ments and inhibits cytokine-mediated migration and
invasion. J Cell Biochem. 2003 May 1;89(1):133–43.
38. Romer DJ, Yearsley KH, Ayers LW. Using a modified
standard microscope to generate virtual slides. Anat Rec B
New Anat. 2003 May;272(1):91–7.
39. Haque M, Davis DA, Wang V, Widmer I, Yarchoan R.
Kaposi's sarcoma-associated herpesvirus (human herpes-
virus 8) contains hypoxia response elements: relevance to
lytic induction by hypoxia. J Virol. 2003
Jun;77(12):6761–8.
40. Mack KD, Jin X, Yu S, Wei R, Kapp L, Green C, Hernd-
ier B, Abbey NW, Elbaggari A, Liu Y, McGrath MS.HIV
insertions within and proximal to host cell genes are a
common finding in tissues containing high levels of HIV
DNA and macrophage-associated p24 antigen expression.
J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308–20.
41. Chaves AA, Mihm MJ, Schanbacher BL, Basuray A, Liu
C, Ayers LW, Bauer JA. Cardiomyopathy in a murine
model of AIDS: evidence of reactive nitrogen species and
corroboration in human HIV/AIDS cardiac tissues. Cardi-
ovasc Res. 2003 Oct 15;60(1):108–18.
42. Mallery SR, Pei P, Landwehr DJ, Clark CM, Bradburn
JE, Ness GM, Robertson FM. Implications for oxidative
and nitrative stress in the pathogenesis of AIDS-related
Kaposi's sarcoma. Carcinogenesis. 2004 Apr;25(4):597–
603. Epub 2003 Dec 4.
43. Killebrew DA, Troelstrup D, Shiramizu B. Preferential
HIV-1 integration sites in macrophages and HIV-associ-
ated malignancies. Cell Mol Biol (Noisy-le-grand).
2004;50 Online Pub:OL581–9.
44. McAllister SC, Hansen SG, Ruhl RA, Raggo CM,
DeFilippis VR, Greenspan D, Fruh K, Moses AV. Kaposi
sarcoma-associated herpesvirus (KSHV) induces heme
oxygenase-1 expression and activity in KSHV-infected
endothelial cells. Blood. 2004 May 1;103(9):3465–73.
Epub 2004 Jan 15.
45. Milligan S, Robinson M, O'Donnell E, Blackbourn DJ.
Inflammatory cytokines inhibit Kaposi's sarcoma-associ-
ated herpesvirus lytic gene transcription in in vitro-
infected endothelial cells. J Virol. 2004 Mar;78(5):2591–
6.
46. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Nar-
vaez AB, Hunt P, Martin JN, Kahn JO, Levy J, McGrath MS,
Hecht FM. Immune activation set point during early HIV
infection predicts subsequent CD4+ T-cell changes inde-
pendent of viral load. Blood. 2004 Aug 15;104(4):942–7.
Epub 2004 Apr 29.
47. Giese T, McGrath MS, Stumm S, Schempp H, Elstner
E, Meuer SC. Differential effects on innate versus adaptive
immune responses by WF10. Cell Immunol. 2004
Jun;229(2):149–58.
48. Wang HW, Trotter MW, Lagos D, Bourboulia D, Hend-
erson S, Makinen T, Elliman S, Flanagan AM, Alitalo K,
Boshoff C. Kaposi sarcoma herpesvirus-induced cellular
reprogramming contributes to the lymphatic endothelial
gene expression in Kaposi sarcoma. Nat Genet. 2004
Jul;36(7):687–93. Epub 2004 Jun 27.
49. Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J,
Hadlock K, Jin X, Reis J, Narvaez A, McGrath MS. Evidence
for systemic immune system alterations in sporadic amyo-
trophic lateral sclerosis (sALS). J Neuroimmunol. 2005
Feb;159(1–2):215–24. Epub 2004 Nov 26.
50. Marchiò S., Alfano M., Primo L., Gramaglia D., Butini
L., Gennero L., De Vivo E., Arap W., Giacca M., Pasqualini
R., Bussolino F. Cell Surface-associated Tat modulates
HIV-1 infection and spreading through a specific interac-
tion with gp120 viral envelope protein. Blood 2005 April
1; 105(7):2802–11
51. Kurokawa M, Ghosh SK, Ramos JC, Mian AM, Toomey
NL, Cabral L, Whitby D, Barber GN, Dittmer DP, Har-
rington WJ Jr. Azidothymidine inhibits NF-kappaB and
induces Epstein-Barr virus gene expression in Burkitt lym-
phoma. Blood. 2005 Jul 1;106(1):235–40. Epub 2005
Mar 24.
52. Orem J, Otieno MW, Banara C, Katongoli-Mbidde E,
Johnson JL, Ayers L, Ghannoum M, Fu P, Feigal EG, Black
J, Whalen G, Ledeman M, Remick SC: Capacity Building
for the Clinical Investigation of AIDS Maligancy in East
Africa. Cancer Detection and Prevention. 2005 April
26;29(2):133–4.
53. Nohle DG, Ayers LW. The tissue microarray data
exchange specification: a document type definition to val-
idate and enhance XML data. BMC Med Inform Decis
Mak. 2005 May 4;5(1):12.
54. Baliga RS, Chaves AA, Jing L, Ayers LW, Bauer JA.
AIDS-related vasculopathy: evidence for oxidative and
inflammatory pathways in murine and human AIDS. AmInfectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 14 of 20
(page number not for citation purposes)
J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1373–
H1380. Epub 2005 May 27.
55. Nohle DG, Hackman BA, Ayers LW. The tissue micro-
array data exchange specification: a web based experience
browsing imported data. BMC Med Inform Decis Mak.
2005 Aug 8;5:25.
56. Salemi M, Lamer SL, Yu S, de Oliveira T, Fitch WM,
McGrath MS. Phylodynamic analysis of Human Immun-
odeficiency Virus Type 1 in Distinct Brain Compartments
Provides a Model for the Neuropathogenesis of AIDS. J
Virol, Sept, 2005. vol 79 No 17, p. 11343–11352.
57. Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ,
and Foreman KE. Gamma secretase inhibitor blocks
Notch activation and induces apoptosis in Kaposi's sar-
coma tumor cells. Oncogene 2005 Sep 22;24:6333–44.
58. Krathwohl MD, Schacker TW, and Anderson JL.
Abnormal Presence of Semimature Dendritic Cells That
Induce Regulatory T Cells in HIV-Infected Subjects. J
Infect Dis 2006 Feb 15; 193:494–504
59. Chaves AA, Baliga RS, Mihm MJ, Schanbacher BL, Bas-
uray A, Liu C, Cook AC, Ayers LW, Baurer JA. Bacterial
Lipopolysaccharide Enhances Cardiac Dysfunction but
Not Retroviral Replication in Murine AIDS: Roles of Mac-
rophage Infiltration and Toll-Like Receptor 4 Expression.
Am J Pathol 2006 Mar;168(3):727–735
60. Wang L, Dittmer DP, Tomlinson CC, Fakhari FD,
Damania B. Immortalization of primary endothelial cells
by the K1 protein of Kaposi's sarcoma-associated herpes-
virus. Cancer Res. 2006 Apr 1;66(7):3658–66
61. Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J,
Lancero M, Narvaez A, McGrath MS. MCP-1 chemokine
receptor CCR2 is decreased on circulating monocytes in
sporadic amyotrophic lateral sclerosis (sALS). J Neuroim-
munol. 2006 Oct;179(1–2):87–93. Epub 2006 Jul 20.
Appendix II – Presentation abstracts using ACSR 
resources
1. Mack K, Wei R, Shiramizu B, Herndier B, Elbaggari A,
Gascon R, Hurt M, McGrath MS. "Sequential Pathogene-
sis" of AIDS malignancies: Clonal insertion of HIV into
macrophages may serve as an early neoplastic event. Key-
stone Symposia on Molecular and Cellular Biology Park
City, UT, March 13–19, 1998
2. King MA, Yip D, Neal DE, Wewers M, Pacht ER, Gadek
J, Diaz PT, Ayers LW. Occult pulmonary hemorrhage in
HIV-positive individuals without AIDS correlates with CT
evidence of emphysema. Am J Respir Crit Care Med
1998:157:A1784.
3. Flickinger M, McGrath M, Silver S, Orenstein J, Miles S,
Ayers LW. AIDS Malignancy Bank: a source for tissue and
biological fluids of HIV-related malignancies. In Proceed-
ings of the Second National AIDS Malignancy Confer-
ence. Bethesda, Maryland, USA. April 6–8, 1998. J Acquir
Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S1–86.
4. Herndier B, Wei R, Abbey N, Weinstein M, Mack K,
Shiramizu B, McGrath MS. Kaposi's sarcoma: a multicellu-
lar, mulitviral process initiated by retroviral insertional
mutagenesis?. In Proceedings of the Second National
AIDS Malignancy Conference. Bethesda, Maryland, USA.
April 6–8, 1998. J Acquir Immune Defic Syndr. 1999 Aug
1;21 Suppl 1:S1–86.
5. Mack K, Wei R, Shiramizu B, Herndier B, Elbaggari A,
Gascon R, Hurt M, McGrath MS. Evidence for HIV medi-
ated cis-activation of the c-fes protooncogene in a subset
of AIDS associated lymphomas. In Proceedings of the Sec-
ond National AIDS Malignancy Conference. Bethesda,
Maryland, USA. April 6–8, 1998. J Acquir Immune Defic
Syndr. 1999 Aug 1;21 Suppl 1:S1–86.
6. Mallery SR, Clark YM, Ness GM, Ayers LW and CM
Hohl. AIDS-Kaposi's Sarcoma Demonstrate Increased
Susceptibility to a Redox Cycling Drug. In Proceedings of
the Second National AIDS Malignancy Conference.
Bethesda, Maryland, USA. April 6–8, 1998. J Acquir
Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S1–86.
7. Flickinger M, McGrath M, Silver S, Orenstein J, Miles S,
Ayers LW. AIDs malignancy bank: a source for tissue and
biological fluids of HIV-related malignancies. 12th World
AIDS Conference Geneva, Switzerland, June 28 – July 3,
1998 [Conference WebSite]
8. McGrath MS, Shiramizu B, McGuire D, Pulliam L,
Herndier B. HIV-associated neoplastic dementia: A model
implicating a role for clonal macrophages. In Proceedings
of the Second National AIDS Malignancy Conference.
Bethesda, Maryland, USA. April 6–8, 1998. J Acquir
Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S1–86.
9. Ayers LW, McGrath MS, Silver S, Miles S, Axiotis C. The
AIDS and Cancer Specimen Bank (ACSB), A NCI Tissue
and Biological Fluids Bank of HIV Infected Tissues. In The
3rd National AIDS Malignancy Conference. Bethesda,
Maryland, USA. May 26–27, 1999. Abstracts. J Acquir
Immune Defic Syndr. 1999 May 1;21(1):A1–41.
10. Flickinger M, McGrath M, Silver S, Orenstein J, Miles
S, Ayers LW, Axiotis C. Tissue and biological fluids banksInfectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 15 of 20
(page number not for citation purposes)
of HIV-related malignancies. In The 3rd National AIDS
Malignancy Conference. Bethesda, Maryland, USA. May
26–27, 1999. Abstracts. J Acquir Immune Defic Syndr.
1999 May 1;21(1):A1–41.
11. Parris L, Ayers LW. Iron Loading of Alveolar Macro-
phages in HIV Positive Patients. The MRI Science Sympo-
sium, Medical/Science Research Initiative, (MRI), Office
of Minority Affairs Columbus, OH, August 1999
12. Abbey NW, McGrath MS, Herndier BG. C-fes proto-
oncogene expression in HIV and non-HIV lymphoid tis-
sues. Seventh Conference on Retroviruses and Opportun-
istic Infections San Francisco, CA, January 30 – February
2, 2000
13. Mack KD, Wei R, Herndier B, Shiramizu B, Abbey N,
Gascon R, Elbaggari A, Hurt M, Earnst T, McGrath MS.
HIV implicated in the cis-activation of c-fes in a subset of
HIV associated lymphomas. Seventh Conference on Ret-
roviruses and Opportunistic Infections San Francisco, CA,
January 30 – February 2, 2000
14. Davis, AT, Mosunjac MB. Cervical dysplasia in women
infected with human immunodeficiency virus {HIV): a
correlation with HIV viral load. United States and Cana-
dian Association of Pathology meeting New Orleans, LA,
March 2000
15. Davis, AT, Walliang R, Mosunjac MI, Mosunjac MB.
Human immunodeficiency virus (HIV)-associated prema-
lignant and malignant lesions by gender in a large inner-
city hospital: a retrospective study. United States and
Canadian Academy of Pathology Annual Meeting New
Orleans, LA, March 25–31, 2000
16. Abbey NW, Silver S, Orenstein JM, Miles S, Ayers L,
Axiotis C, McGrath MS. The AIDS and Cancer Specimen
Bank. In The 4th International AIDS Malignancy Confer-
ence. Bethesda, Maryland, USA. May 16–18, 2000.
Abstracts. J Acquir Immune Defic Syndr. 2000 Mar
1;23(3):A1–37.
17. Ayers LW, and The Midregion ACSB Consortium. The
Ohio State University, Emory University, Rush University,
University of Texas, Southwestern and Vanderbilt Univer-
sity: Application of the Tissue Microarray (TMA) method
by the Midregion AIDS and Cancer Specimen Bank
(ACSB) to prepare study sets from HIV infected and con-
trol tissues. In The 4th International AIDS Malignancy
Conference. Bethesda, Maryland, USA. May 16–18, 2000.
Abstracts. J Acquir Immune Defic Syndr. 2000 Mar
1;23(3):A1–37.
18. McGrath MS, Elbaggari A, Gascon R, Herndier B,
Meuer S, Giese T, Zenger E. Quantitation of AIDS lym-
phoma associated macrophage RNA. implications for
"sequential pathogenesis" of extranodal lymphoma. In
The 4th International AIDS Malignancy Conference.
Bethesda, Maryland, USA. May 16–18, 2000. Abstracts. J
Acquir Immune Defic Syndr. 2000 Mar 1;23(3):A1–37.
19. Ayers LW, Romer D, Yi H, The Midregion AIDS and
Cancer Specimen Bank (ACSB). Cancer Research Data
from Tissue Microarrays (TMA) and the Associated Patient
Demographic and Clinical Information Facilitated by a
Graphical Microsoft Access Database. Cancer research
data from tissue microarrays (TMA) and the associated
patient demographic and clinical information facilitated
by a graphical Microsoft Access database. Third Annual
Comprehensive Cancer Center Scientific Meeting Dublin,
OH, January 24, 2001
20. Ayers LW, Romer D, Yi H, and The Midregion AIDS
and Cancer Specimen Bank (ACSB), and Division of
Informatics, Department of Pathology, The Ohio State
University, Columbus, OH 43210. AIDS-Associated
Malignant Tissue Research using Tissue Micro-Arrays
(TMAs) Facilitated by a Graphical Microsoft Access Data-
base. Fifth International AIDS Malignancy Conference
Bethesda, MD, April 23–26, 2001 [program only]
21. Garcia D, McGrath MS, Silver S, Miles S, Ayers L, Axi-
otis C. AIDS and Cancer Specimen Bank. Fifth Interna-
tional AIDS Malignancy Conference Bethesda, Maryland,
26, April 23–25, 2001 [program only]
22. Ayers L, Romer D. Development of a Tissue Array Data
System (TADS) for AIDS and Cancer Specimen Bank
(ACSB). In Advancing Pathology Informatics, Imaging,
and the Internet (APIII 2001). Arch Pathol Lab Med. 2002
Jul;126(7):791–792.
23. Romer D, Ayers L. Adding a Robotic Stage to the Desk-
top Microscope and Creating Virtual Slides with Image
Pro Plus. In Advancing Pathology Informatics, Imaging,
and the Internet (APIII 2001). Arch Pathol Lab Med. 2002
Jul;126(7):792.
24. Garcia DL, McGrath MS, Silver S, Orenstein J, Ayers L.
AIDS and Cancer Specimen Bank. The XIV International
AIDS Conference, 2002 Abstract no. C11034.
25. Ayers LW, Romer D, Yi H. The Midregion AIDS and
Cancer Specimen Bank (ACSB). A Tissue Array Database
System (TADS) for the AIDS Cancer and Specimen Bank
(ACSB) Developed to Manage Numerical and Digital
Image Cancer Research Data From Tissue MicroarraysInfectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 16 of 20
(page number not for citation purposes)
(TMAs). The Fourth Annual Comprehensive Cancer
Center Scientific Meeting Dublin, OH, January 11, 2002
26. Mihm M, Schanbacher BL, Basuray A, Lui C, Amann
DM, Ayers LW, John Anthony Bauer, JA. Protein Oxida-
tion and Immune Cell Trafficking in Human AIDS-
Related Cardiomyopathy. The Ohio State University Med-
ical Center Graduate and Postgraduate Research Day April
4, 2002
27. Ayers LW, D. Romer, H Yi. The Midregion AIDS and
Cancer Specimen Bank (ACSB). A Tissue Array Manage-
ment System (TAMS) for the AIDS Cancer and Specimen
Bank (BANK) Developed to Manage Numerical and Dig-
ital Image Cancer Research Data From Tissue Microarrays
(TMAs). Sixth International Conference on Malignancies
in AIDS and Other Immunodeficiencies: Basic, Epidemio-
logic and Clinical Research Bethesda, MD, April 22–24,
2002 [program only]
28. Garcia DL, Ayers LW, Axiotis C, Orenstein J, Miles S,
Silver S, McGrath MS. ACSB CODCC, AIDS and Cancer
Specimen Bank: A Resource for Your Research. Sixth Inter-
national Conference on Malignancies in AIDS and Other
Immunodeficiencies: Basic, Epidemiologic and Clinical
Research Bethesda, MD, April 22–24, 2002 [program
only]
29. McGrath MS, Jin X, Yu S, Wei R, Kapp L, Green C,
Abbey NW, Elbaggari A, Liu Y, Herndier B, Mack KD. HIV
insertions within and proximal to host cell genes are a
common finding in tissues containing high levels of HIV
DNA and macrophage associated P24 antigen expression.
Fifth International Workshop on HIV, Cells of Macro-
phage/Dendritic Lineage and Other Reservoirs Rome,
Italy, 15, October 13–15, 2002.
30. Hadlock KG, Miller RG, Gelinas D, Jin X, Reis J, Mass
J, McGrath MS. Elevated reactivity to HML-2/HERV-K but
not other endogenous retroviruses in ALS. 55th Annual
Meeting of the American Academy of Neurology Hono-
lulu, HI, March 29-April 5, 2003
31. McGrath MS, Gascon RL, Miller RG, Gelinas D, Yu S,
Zhang RZ, Frydman B, Marton L. Pathogenesis of ALS:
Removal of abnormal macrophages (MO) and source of
pathogenic factor production from ALS blood in vitro
with a novel polyamine analogue, SL-11047. 55th Annual
Meeting of the American Academy of Neurology Hono-
lulu, HI, March 29-April 5, 2003
32. Ayers LW, Mihm MJ, Hackman B, Bauer JA, Midregion
AIDS and Cancer Specimen Resource (ACSR). AIDS
Patients have High Levels of Protein Nitration within
Actively HIV Infected Cells. Does this Cause Organ Mal-
function and Cancer? Abstracts from the Seventh Interna-
tional Conference on Malignancies in AIDS and Other
Immunodeficiencies: Basic, Epidemiologic and Clinical
Research, Natcher Conference Center Bethesda, MD, April
28–29, 2003.http://www.cancer.gov/dctd/aids/confer
ence 2003:86.
33. Silver S, Ayers L, Orenstein J, McGrath M. Aids and
Cancer Specimen Resource: a Resource for Your Research.
In Abstracts of the ISBER Annual Meeting: Biodiversity
and International Regulations. May 4–7, 2003, Philadel-
phia, Pennsylvania, USA. Biotech Histochem. 2003 Jun-
Aug;78(3–4):207–28.
34. Nohle DG, Hackman BA, Ayers LW. Web-based Vir-
tual Tissue Micro-array Slides with clinical Data F or
Researchers in HTML, Excel and API Standard XML Data
Exchange Specification Formats Produced with Microsoft
Office® Applications. In Advancing Practice, Instruction,
and Innovation Through Informatics (APIII 2003): Scien-
tific Session and E-Poster Abstracts. Arch Pathol Lab Med.
2004 Oct;128(10):1089–1123.
35. Bachowski GJ, Birdsong GG, Lau SK, Tadros TS, Oprea
GM. Evolution of High Grade Squamous Intraepithelial
Lesion (HSIL) in HIV-Positive Women compared to the
General Population: 5 year Follow-Up. United States and
Canadian Academy of Pathology Meeting Vancouver,
Canada. March 17–19, 2004
36. Yu S, Lamers S, Jin X, Reis J, McGrath MS. Restricted
HIV genomic variability in AIDS dementia and lym-
phoma. Keystone Symposia, Molecular mechanisms of
HIV Pathogenesis Whistler, British Columbia, April 12–
18, 2004 [program only]
37. Ayers LW, Jin X, Bauer JA, McGrath M. HIV Integration
Sites Found in Cardiac Myocyte Nuclei and Adjacent
PCNA Positive Macrophage Nuclei from AIDS Cardi-
omopathy Heart Tissue. Abstracts from the 8th Interna-
tional Conference on Malignancies in AIDS and Other
Immunodeficiencies: Basic, Epidemiologic and Clinical
Research Bethesda, MD, April 29–30, 2004.http://
www.cancer.gov/dctd/aids/conference 2004:74.
38. Lamers S, Yu S, McGrath MS. Genetic analysis of HIV-
1 from site-specific brain tissue: Does compartmentaliza-
tion occur within the brain? 11th International Work-
shop, HIV Dynamics and Evolution Stockholm, Sweden,
April 29-May 4, 2004
39. Nohle DG, Hackman B, Ayers L. Tissue Micro-Array
Data Using TMA Standard and Public Tool Linked Legend
and Clinical Details at ACSR.Mid-Region.org. Tissue
Micro-Array Data Using TMA Standard and Public ToolInfectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 17 of 20
(page number not for citation purposes)
Linked Legend and Clinical Details at acsr.mid-region.org.
Abstracts from the 8th International Conference on Malig-
nancies in AIDS and Other Immunodeficiencies: Basic,
Epidemiologic and Clinical Research, Natcher Conference
Center Bethesda, MD, April 29–30, 2004.http://www.can
cer.gov/dctd/aids/conference 2004:75.
40. McGrath MS, Garcia D, Ayers L, Silver S, Orenstein J,
Lamers S. AIDS and cancer specimen resource: A resource
for HIV reservoir research. The XV International AIDS
Conference, 2004 Abstract no. A10525.
41. McGrath MS, Yu S, Jin X, Reis J, Lamers S. Restricted
HIV genomic variability in AIDS dementia and lym-
phoma. The XV International AIDS Conference, 2004
Abstract no. ThOrA1399.
42. Silver S, Ayers L, Orenstein J, McGrath M. AIDS and
Cancer Specimen Resource (ASCR): A Resource for Your
Research. International Society of Biological and Environ-
mental Repositories, Perugia, Italy, October 2004
43. Lee Z, Muzic R, Gagon D. Dynamic PET for Animal
Model of HCC. Presented at Annual Meeting of Biomedi-
cal Engineering Society, October 2004
44. Silver S, Ayers L, Orenstein J, McGrath M. The AIDS
and Cancer Specimen Resource (ACSR) Model for Cancer
Research Facilitation. International Society of Biological
and Environmental Repositories, Bellevue, WA, May 2005
45. Nohle DG, Hackman BA, Ayers LW. A Document Type
Definition for the API standard tissue micro-array XML
data exchange specification, In Advancing Practice,
Instruction, and Innovation Through Informatics (APIII
2004): Scientific Session and E-Poster Abstracts. Arch
Pathol Lab Med. 2005 Jun;129(6):811–834.
46. Lamers SL, Salemi M, McGrath MS. HIV-1 envelope
domains derived from AIDS related lymphoma tissues
display unique substitution patterns as compared to pub-
lished envelope domains. The 3rd IAS Conference on HIV
Pathogenesis and Treatment, 2005 Abstract no.
MoPe14.2B17.
47. McGrath MS, Lamers SL, Salemi M. HIV sequence evo-
lution in the brain: Distinctly different evolutionary path-
ways between HAD and primary CNS lymphoma
associated strains of HIV. The 3rd IAS Conference on HIV
Pathogenesis and Treatment, 2005 Abstract no.
WePe8.13B04.
48. Nohle DG, Hackman BA, Ayers LW. Adding style to
the API Tissue Micro-array Data Exchange Specification,
In Advancing Practice, Instruction, and Innovation
Through Informatics (APIII 2005): Scientific Session and
E-Poster Abstracts. Arch Pathol Lab Med.
49. McGrath MS, Salemi M, Lamers SL. Genetic Analysis of
HIV in AIDS Malignancies. Oral presentation by Michael
S. McGrath, MD, PhD at the 2005 International Meeting
of the Institute of Human Virology, Baltimore, MD, Aug
29-Sep 2, 2005.
50. Dittmer DP, Staudt MR, Fakhari FD, Hilscher C, Sin S,
Chaput A. Regulation of KSHV Latent gene expression.
Abstracts from the 9th International Conference on Malig-
nancies in AIDS and Other Acquired Immunodeficiencies:
Basic, Epidemiologic and Clinical Research, Marriott
Bethesda North Hotel & Conference Center, North
Bethesda, MD, September 26–27, 2005. http://www.can
cer.gov/dctd/aids/conference
51. Levine AL, Seaberg EC, Hessol NA, Preston-Martin S,
Li M, Silver S, Cohen M, Anastos K, Minkoff H, Black J,
Watts DH. HIV is not a risk factor for lung cancer in
women: data from the women's interagency HIV study
(WIHS). Abstracts from the 9th International Conference
on Malignancies in AIDS and Other Acquired Immunode-
ficiencies: Basic, Epidemiologic and Clinical Research,
Marriott Bethesda North Hotel & Conference Center,
North Bethesda, MD, September 26–27, 2005. http://
www.cancer.gov/dctd/aids/conference
52. Mbulaiteye SM, Katabira ET, Wabinga H, Parkin DM,
Virgo P, Ochai R, Workneh M, Coutinho A, Engels EA.
Spectrum of cancers among HIV-infected persons in
Africa: the Uganda AIDS-cancer registry match study.
Abstracts from the 9th International Conference on Malig-
nancies in AIDS and Other Acquired Immunodeficiencies:
Basic, Epidemiologic and Clinical Research, Marriott
Bethesda North Hotel & Conference Center, North
Bethesda, MD, September 26–27, 2005. http://www.can
cer.gov/dctd/aids/conference
53. McGrath MS, Lamers S, Salemi M. Evolutionary dis-
tinct forms of HIV in AIDS lymphoma and dementia.
Abstracts from the 9th International Conference on Malig-
nancies in AIDS and Other Acquired Immunodeficiencies:
Basic, Epidemiologic and Clinical Research, Marriott
Bethesda North Hotel & Conference Center, North
Bethesda, MD, September 26–27, 2005. http://www.can
cer.gov/dctd/aids/conference
54. McGrath MS, Lamers SL, Salemi M. HIV infected mac-
rophages associated with dementia (HAD) and lym-
phoma (ARL) show distinct patterns of evolution in vivo.
Poster presentation at the 6th International Workshop on
HIV, Cells of Macrophage/Dendritic Lineage & Other Res-
ervoirs, Varenna, Italy, Oct 5–7 2005.Infectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 18 of 20
(page number not for citation purposes)
55. Curry CL, Reed LL, Nickoloff BJ, and Foreman KE. Tar-
geting Notch in Kaposi's sarcoma inhibits tumorigenesis.
Oral presentation at Society of Investigative Dermatology
Meeting, 2004; Oral presentation at Seventh International
Workshop on Kaposi's Sarcoma-Associated Herpesvirus
(KSHV/HHV8) and Related Agents, 2004; Poster presenta-
tion at EMBO Notch Workshop, 2005.
56. Shikuma CM, Shiramizu B, McGrath M, Shagrun L,
Chow D, Gerschenson M. HIV Infected Monocytes and
Macrophages in Adipose Tissue Contribute to the Devel-
opment of Lipatrophy. 7th International Workshop on
Adverse Drug Reactions and Lipodystrophy in HIV, 13–16
Nov 2005 in Dublin, Ireland.
57. Huerta-Yepez S, Vega M, Gui D, Said J, Bonavida B.
Analysis of YY1 and XIAP expression, proteins that regu-
late resistance, in AIDS-NHL tissue arrays. Blood (ASH
Annual Meeting Abstracts) 2005 106: Abstract 1933 2005
Dec;106 (11).
58. Zhang RZ, Gascon R, Miller RG, Gelinas DF, Mass J,
Lancero M, Narvaez A, McGrath MS. MCP-1 Chemokine
Receptor CCR2 Is Absent on Circulating Monocytes in
Sporadic ALS. Poster presentation at the 16th Interna-
tional Symposium on ALS/MND in Dublin, Ireland, Dec
8–10, 2005.
59. Do H, Hadlock KG, Miller RG, Yu S, Mass J, Zhang RZ,
Gascon R, Narvaez A, Katz J, McGrath, MS. Transcriptional
Program of Peripheral Blood Cells in ALS: Evidence for
Systemic Immune Activation. Poster presentation at the
16th International Symposium on ALS/MND in Dublin,
Ireland, Dec 8–10, 2006.
60. Jin X, Hadlock KG, Yu S, Do H, Miller R, Mass J, Katz
J, Zhang RZ, Gascon R, McGrath MS. Mutational Recovery
of Viral Open Reading Frames in Selected HERV-K-Related
Endogenous Retro Viruses in ALS Patients. Poster presen-
tation at the 16th International Symposium on ALS/MND
in Dublin, Ireland, Dec 8–10, 2005.
61. Yu S, Hadlock KG, Miller RG, Do H, Mass J, Zhang RZ,
Gascon R, Lancero M, Narvaez A, Katz J, McGrath MS.
Detection of ALS by Quantitative Real Time RT-PCR of
Peripheral Blood Cells. Poster presentation at the 16th
International Symposium on ALS/MND in Dublin, Ire-
land, Dec 8–10, 2005.
62. Gruzman AL, Prasad MD, Miller RG, Lingappa V & Liu
J. Identification of Biomarkers for ALS. Poster presenta-
tion at the 16th International Symposium on ALS/MND
in Dublin, Ireland, Dec 8–10, 2005.
63. Marchiò S., Bagnod R., Traversa S., Fumero S., Bus-
solino F.: A new peptide inhibitor of HIV-1 entry. Poster
presented at the congress "PepTalk", San Diego, CA. Janu-
ary 11th-13th, 2006.
64. McGrath MS, Galligan D, Lamers S, Salemi M. HIV
Infected Macrophages Associated with Lymphoma (ARL)
Show Distinct Patterns of Evolution in Vivo. Accepted for
poster presentation at 13th Conference on Retroviruses
and Opportunistic Infections, Denver CO, Feb 5–9, 2006.
65. Galligan D, Lamers SL, de Oliveira T, Salemi, M,
McGrath MS. HIV-1 Molecular Dynamics in Multisite
Lymphoma Biopsies. Accepted for poster presentation at
HIV Pathogenesis Symposium, Keystone CO, Mar 27-Apr
2, 2006.
66. Lamers SL, Salemi T, de Oliveria T, Beason S, Comp-
ton R, Goodenow M, McGrath MS. A Protocol for HIV-1
env Alignments Assists in Determining the Evolutionary
Dynamics of the V1, V2 and V4 Hypervariable Domains.
Presented to HIV Pathogenesis Symposium, Keystone CO,
Mar 27-Apr 2, 2006
67. Nohle DG, Ayers LW. Extending the API TMA data
exchange specification to single specimen and cutting
edge matrix assembly (CEMA). ASIP INFORMATICS,
Experimental Biology 2006: Advancing the Biomedical
Frontier. The Moscone Convention Center, San Francisco,
CA, April 1 – 5, 2006.
68. Ayers LW, McGrath MS, Silver S, Orenstein J, Bhatia K.
RNA, DNA and Molecular Targets in Archived Paraffin-
embedded Tissue Samples, 1980–2005. Presented to
International Society for Biological and Environmental
Repositories (ISBER) 2006 Annual Meeting, Bethesda,
MD. April 30-May 3, 2006.
69. Ayers LW, Hackman BA, Nohle DG. Software-Assisted
Image Analysis for ACSR Tissue Microarays (TMA) Quality
Control. Presented to International Society for Biological
and Environmental Repositories (ISBER) 2006 Annual
Meeting, Bethesda, MD. April 30-May 3, 2006.
70. Kulkarni AL, Handorf CR. Legal Issues Involving
Research Utilization of Archived Formalin Fixed Paraffin
Embedded Tissue. Presented to International Society for
Biological and Environmental Repositories (ISBER) 2006
Annual Meeting, Bethesda, MD. April 30-May 3, 2006.
71. Ayers LW, McGrath MS, Silver S. Orenstein J., Bhatia
K. The AIDS and Cancer Specimen Resource (ACSR) pro-
vides Kaposi's sarcoma (KS) and non-Hodgkin's lym-
phoma (NHL) specimens for translational research.
Presented at the 9th Annual Workshop on KS AssociatedInfectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 19 of 20
(page number not for citation purposes)
Herpesvirus & Related Viruses, Cape Cod, MA. July 12–15,
2006.
72. Carroll PA. Latent KSHV Infection of Endothelial Cells
Activates Hypoxia-Induced Factors. Accepted for oral pres-
entation (Abstract 36) at 9th Annual KSHV Workshop,
Hyannis, MA. July 12–15, 2006. (Michael Lagunoff lab)
73. Lagos D, Trotter MW, Vart RJ, Wang HW, Matthews
NC, Hansen A, Gotch F, Boshoff C. Kaposi Sarcoma Her-
pesvirus Employs Transcriptional Mechanisms to Regu-
late Antigen Presentation in Lymphatic Endothelial Cells.
Accepted for oral presentation (abstract 64) at 9th Annual
KSHV Workshop, Hyannis, MA. July 12–15, 2006.
74. Lamers SL, Galligan D, Zhao L, Yu S, Shagrun L, De
Oliveria T, Salemi M, McGrath MS. Multi-site tissue
autopsy samples from patients with dementia and AIDS
related lymphoma show distinct patterns of HIV evolu-
tion in vivo. Poster presentation at the XVI International
AIDS Conference in Toronto ON. August 13–18, 2006
75. Nohle DG, Hackman BA, Ayers LW. Software-assisted
visual analysis and review of tissue microarray (TMA)
images facilitated by XML. Poster presentation at APIII
2006 11th Annual Conference, Vancouver BC, August 15–
18, 2006.
76. Ayers LW, Hackman BA, McGrath MS, Silver S, Oren-
stein J, Bhatia K. HIV/AIDS-related Lymphoma Immu-
nophenotypes in Biopsy Samples from Patients During
Pre and Post HAART Treatment Periods. Presented to 10th
International Conference on Malignancies in AIDS and
Other Acquired Immunodeficiencies: Basic, Epidemio-
logic and Clinical Research, North Bethesda, MD, October
16–17 2006.
77. Shagrun LS, Morris A, McGrath MS. "ProMacs" in
cases of HIV+ and HIV- Large Cell Lymphoma. Presented
to 10th International Conference on Malignancies in
AIDS and Other Acquired Immunodeficiencies: Basic,
Epidemiologic and Clinical Research, North Bethesda,
MD, October 16–17 2006.
78. Mwanda OW, Orem J, Fu P, Banura C, Kakembo J,
Ness A, Johnson J, Subbiah V, Bako J, Black J, Katongole-
Mbidde E, Remick SC. Dose modified oral chemotherapy
for AIDS-related non-Hodgkin's Lymphoma (AR-NHL) in
East Africa: Impact on CD4+ count and HIV-1 replication;
and retrospective look at similar regimen in pre-HAART
era in the USA. AB# 13 presented to 10th International
Conference on Malignancies in AIDS and Other Acquired
Immunodeficiencies in North Bethesda, Maryland; Octo-
ber 16–17, 2006.
79. Mwanda OW, Orem J, Fu P, Banura C, Kakembo J,
Ness A, Johnson J, Subbiah V, Bako J, Black J, Katongole-
Mbidde E, Remick SC. Dose modified oral chemotherapy
for AIDS-related non-Hodgkin's Lymphoma (AR-NHL) in
East Africa. AB# 47 presented to 10th International Confer-
ence on Malignancies in AIDS and Other Acquired Immu-
nodeficiencies in North Bethesda, Maryland; October 16–
17, 2006.
80. Bako J, Mwanda OW, Orem J, Fu P, Subbiah V, Banura
C, Kakembo J, Ness A, Johnson J, Katongole-Mbidde E,
Remick SC. Comparative retrospective study of patients at
diagnosis with AIDS-related non-Hodgkin's Lymphoma
(AR-NHL) treated with oral chemotherapy in the pre-
HAART era in East Africa and the USA. AB# 48 presented
to 10th International Conference on Malignancies in AIDS
and Other Acquired Immunodeficiencies in North
Bethesda, Maryland; October 16–17, 2006.
81. Subbiah V, Mwanda OW, Orem J, Fu P, Banura C,
Kakembo J, Ness A, Johnson J, Bako J, Katongole-Mbidde
E, Remick SC. Analyses of prognostic factors for survival in
East African patients with AIDS-related non-Hodgkin's
Lymphoma (AR-NHL) treated with dose modified oral
chemotherapy. AB# 50 presented to 10th International
Conference on Malignancies in AIDS and Other Acquired
Immunodeficiencies in North Bethesda, Maryland; Octo-
ber 16–17, 2006.
82. Orem J, Mwanda OW, Fu P, Banura C, Kakembo J,
Ness A, Johnson J, Subbiah V, Bako J, Katongole-Mbidde
E, Remick SC. Implications of oral chemotherapy for
AIDS-related non-Hodgkin's lymphoma (AR-NHL). AB#
51 presented to 10th International Conference on Malig-
nancies in AIDS and Other Acquired Immunodeficiencies
in North Bethesda, Maryland; October 16–17, 2006.
83. Zhang RZ, Miller RG, Gascon R, Gelinas DF, Katz J,
Mass J, Scholtz D, Lancero M, Narvaez A, McGrath MS.
Evidence for abnormal monocyte immunoglobulin recep-
tor expression in sporadic amyotrophic lateral sclerosis
(sALS). Accepted for Poster presentation at the 17th Inter-
national Symposium on ALS/MND in Yokohama, Japan,
November 30 – December 2, 2006
Notes
Grant Support: National Cancer Institute (NCI), U01-
CA66529, U01-CA96230, and U01-CA066531
Requests for reprints: Debra Garcia, ACSR CODCC, 995
Potrero Avenue, Building 80, Ward 84, San Francisco, CA
94110
Acknowledgements
David Nohle produced statistics, performed technical writing and adapted 
the manuscript to meet the requirements of this journal. Debra Garcia Infectious Agents and Cancer 2007, 2:7 http://www.infectagentscancer.com/content/2/1/7
Page 20 of 20
(page number not for citation purposes)
developed charts and Melissa Belenzo edited the manuscript to incorporate 
comments.
The following are acknowledged for their contributions to the develop-
ment of the ACSR:
• University of California San Francisco: Debra Garcia, Josh Senyak, Patrick Oh, 
Melissa Belenzo, Amy Narvaez.
• George Washington University: Farrell Hartigan, John Bayerl.
• The Ohio State University: Barbara Hackman, David Nohle; Grady Health Sys-
tems, Emory University, Atlanta, GA: George Birdsong, M.D. and Walliang 
Rosene; Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL: John Coon, 
M.D., PhD. and Kelly Kiser; University of Tennessee, Memphis: Anand 
Kulkarni, M.D.; Case Western Reserve University, Cleveland, OH: Scot Remick, 
M.D. with East Africa: Edward MBidde, M.B., ChB and Betty Rebecca 
Namwase (Uganda), Mwanda W. Otieno, M.B, ChB and Onyango James I. 
Obsila (Kenya).
• National Cancer Institute: Office of AIDS-related Malignancy: Kishor Bhatia, 
PhD., MRCPath. and Jodi Black, PhD. (consultant)
References
1. Quinn TC, Overbaugh J: HIV/AIDS in women: an expanding epi-
demic.  Science 308(5782):1582-3. 2005 Jun 10;
2. Kest H, Brogly S, McSherry G, Dashefsky B, Oleske J, Sege GR 3rd:
Malignancy in perinatally human immunodeficiency virus-
infected children in the United States.  Pediatr Infect Dis J 2005,
24(3):237-242.
3. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A,
Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A,
Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S:
Swiss HIV Cohort.. Cancer risk in the Swiss HIV Cohort
Study: associations with immunodeficiency, smoking, and
highly active antiretroviral therapy.  J Natl Cancer Inst
97(6):425-32. 2005 Mar 16;
4. Bernstein WB, Little RF, Wilson WH, Yarchoan R: Acquired immu-
nodeficiency syndrome-related malignancies in the era of
highly active antiretroviral therapy.  Int J Hematol 2006,
84(1):3-11.
5. National Cancer Institute: Tissue and Biological Fluids Banks of
HIV-Related Malignancies NIH Guide RFA: CA-94-003 P.T.
2006,  23(2): [http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-94-
003.html]. 1994 Jan 14 [cited 2006 Oct 9]
6. AIDS and Cancer Specimen Resource national web site   [http:/
/acsr.ucsf.edu]
7. National Cancer Institute. Tissue and Biological Fluids Banks
of HIV-Related Malignancies NIH Guide RFA: CA-02-001
[http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-02-001.html]. 2001
Apr 24 [cited 2006 Oct 9]
8. Ng V, Hurt M, Herndier BH, Fry KE, McGrath MS: Vh Gene used by
HIV-1 Associated Lymphoproliferations.  AIDS Res Hum Retrovi-
ruses 1997, 13:135-149.
9. McGrath MS, Shiramizu B, Herndier BG: Clonal HIV in the patho-
genesis of AIDS-related lymphoma: Sequential pathogenesis.
In Infectious Causes of Cancer: Targets for intervention Edited by: James
Goedert. Totowa, NJ: Humana Press; 2000:231-242. 
10. Zenger E, Abbey NW, Weinstein MD, Gofman I, Millward C, Gascon
R, Elbaggari A, Herndier BG, McGrath MS: Injection of human pri-
mary effusion lymphoma cells or associated macrophages into
SCID mice causes murine lymphomas.  Cancer Research 2002,
62:5536-5542.
11. Aoki Y, Yarchoan R, Braun J, Iwamoto A, Tosato G: Viral and cellular
cytokines in AIDS-related malignant lymphomatous effusions.
Blood 2000, 96:1599-1601.
12. Wang HS, Totter MWB, Lagos D, Bourboulia D, Henderson S, Makinen
T, Elliman S, Flanagan AM, Alitalo K, Boshoff C: Kaposi sarcoma her-
pesvirus induced cellular reprogramming contributes to the
lymphatic endothelial gene expression in Kaposi sarcoma.  Nat
Genet 2004, 36(7):687-93. Epub 2004 Jun 7.
13. Napolitano LA, Grant RM, Schmidt D, DeRosa S, Herzenberg L, Deeks
S, Loftsu R, McCune JM: Circulating interleukin-7 levels are cor-
related with CD4+ lymphopenia and vial load in HIV-1
infected individuals: implications for disease progression.
Nature Med 2001, 7:73-79.
14. Przybylski GK, Goldman J, Ng VL, McGrath MS, Herndier BG,
Schenkein DP, Monroe JG, Silberstein LE: Evidence for early B-cell
activation preceding the development of Epstein-Barr virus-
negative acquired immunodeficiency syndrome-related lym-
phoma.  Blood 1996, 88:4620-4629.
15. Palefsky JM, Holly EA, Hogeboom CJ, Ralston ML, DaCosta MM, Botts
R, Berry JM, Jay N, Darragh TM: Virologic, immunologic, and clin-
ical parameters in the incidence and progression of anal squa-
mous intraepithelial lesions in HIV-positive and HIV-negative
homosexual men.  J Acquir Immune Defic Syndr Hum Retrovirol
17(4):314-9. 1998 Apr 1
16. Martin J, Amad Z, Cossen C, Lam PK, Kedes D, Page-Shafer K, Osmond
D, Forghani B: Use of epidemiologically well-defined subjects
and existing immunofluorescence assays to calibrate a new
enzyme immunoassay for human herpesvirus 8 antibodies.  J
Clin Microbiol 2000, 38:696-701.
17. Mack KD, Jin X, Yu S, Wei R, Kapp L, Green C, Hemdier B, Abbey NW,
Elbaggari A, Liu Y, McGrath MS: HIV insertions within and proxi-
mal to host cell genes are a common finding in tissues contain-
ing high levels of HIV DNA and macrophage-associated p24
antigen expression.  J Acquir Immune Defic Syndr 33(3):308-20. 2003
Jul 1;
18. Killebrew DA, Troelstrup D, Shiramizu B: Preferential HIV-1 inte-
gration sites in macrophages and HIV-associated malignan-
cies.  Cell Mol Biol (Noisy-le-grand) 2004, 50 Online Pub:OL581-9.
19. Salemi M, Lamer SL, Yu S, de Oliveira T, Fitch WM, McGrath MS: Phy-
lodynamic analysis of human immunodeficiency virus type 1 in
distinct brain compartments provides a model for the neu-
ropathogenesis of AIDS.  J Virol 2005, 79(17):11343-52.
20. Baliga RS, Chaves AA, Jing L, Ayers LW, Bauer JA: AIDS-related vas-
culopathy: evidence for oxidative and inflammatory pathways
in murine and human AIDS.  Am J Physiol Heart Circ Physiol 2005,
289(4):H1373-H1380. Epub 2005 May 27
21. Chaves AA, Mihm MJ, Schanbacher BL, Basuray A, Liu C, Ayers LW,
Bauer JA: Cardiomyopathy in a murine model of AIDS: evi-
dence of reactive nitrogen species and corroboration in
human HIV/AIDS cardiac tissues.  Cardiovasc Res 60(1):108-18.
2003, Oct 15;
22. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton
S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue micro-
arrays for high-throughput molecular profiling of tumor spec-
imens.  Nat Med 1998, 4(7):844-7.
23. Mid-Region ACSR web site   [http://www.acsr.mid-region.org]
24. Nohle DG, Hackman BA, Ayers LW: The tissue micro-array data
exchange specification: a web based experience browsing
imported data.  BMC Med Inform Decis Mak 2005, 5:25.
25. Nohle DG, Ayers LW: The tissue microarray data exchange
specification: a document type definition to validate and
enhance XML data.  BMC Med Inform Decis Mak 2005, 5(1):12.
26. Berman JJ, Edgerton ME, Friedman BA: The tissue microarray data
exchange specification: a community-based, open source tool
for sharing tissue microarray data.  BMC Med Inform Decis Mak
3(1):5. 2003 May 23;
27. Department of Health and Human Services: 45 CFR (Code of Fed-
eral Regulations), 164.514 (6)(2)(i).  In Standards for Privacy of Indi-
vidually Identifiable Health Information (final) US Government Printing
Office, Washington DC; 2002. 
28. International Society for Biological and Environmental Repositories:
Best Practices for Repositories I: Collection, Storage, and
Retrieval of Human Biological Materials for Research.  Cell Pre-
serv Technol  [http://www.isber.org/Pubs/BestPractices.pdf]. 2005 Mar;1
29. National Cancer Institute Office of Biorepositories and Biospecimen
Research:  First-Generation Guidelines for NCI-Supported
Biorepositories.   [http://biospecimens.cancer.gov/biorepositories/
guidelines_glossary.asp].
30. AIDS Clinical Trials Group Repository Advisory Group: ACTG Spec-
imen Repository Guidelines.   [http://aactg.s-3.com/pub/download/
specimen/specshipinstruct.pdf]. 2006 May 19 [cited 2006 Oct 9]
31. Srinivasan M, Sedmak D, Jewell S: Effect of fixatives and tissue
processing on the content and integrity of nucleic acids.  Am J
Path 2002, 161(6):1961-1971.
32. Jewell S, Srinivasan M, McCart L, Williams N, Grizzle WH, LiVolsi V,
MacLennan G, Sedmak DD: Analysis of the molecular quality of
human tissue. An experience from the Cooperative Human
Tissue Network.  Am J Clin Path 2002, 118(5):733-740.
33. AIDS Malignancy Consortium web site   [http://pub.emmes.com/
study/amc/public/links/links.htm]